Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema.
Adaptor Proteins, Signal Transducing
/ metabolism
Aged
Aqueous Humor
/ physiology
Blood-Retinal Barrier
/ pathology
Chemokine CCL5
/ metabolism
Cytokines
/ metabolism
Diabetes Complications
/ pathology
Diabetes Mellitus
/ pathology
Diabetic Retinopathy
/ pathology
Fas Ligand Protein
/ metabolism
Female
Fluorescein Angiography
Humans
Laser Coagulation
/ methods
Macular Edema
/ pathology
Male
Microglia
/ cytology
Middle Aged
Prospective Studies
Retina
/ metabolism
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
/ metabolism
Visual Acuity
/ physiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 07 2019
11 07 2019
Historique:
received:
02
04
2019
accepted:
21
06
2019
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
22
10
2020
Statut:
epublish
Résumé
Subthreshold micropulse laser (SMPL) is a tissue-sparing technique whose efficacy is demonstrated for diabetic macular edema (DME) treatment. However, its mechanism of action is poorly known. A prospective observational study was performed on naïve DME patients treated with SMPL, to evaluate the changes of aqueous humor (AH) inflammatory and vaso-active biomarkers after treatments. AH samples of eighteen DME eyes were collected before and after SMPL. Ten non-diabetic AH samples served as controls. Full ophthalmic evaluation, spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography were performed in DME group. Glass chip protein array was used to quantify 58 inflammatory molecules. Central retinal thickness (CRT) and visual acuity were also monitored. Several molecules showed different concentrations in DME eyes versus controls (p value < 0.05). Fas Ligand (FasL), Macrophage Inflammatory Proteins (MIP)-1α, Regulated on Activation Normal T Cell Expressed and Secreted (RANTES) and Vascular Endothelial Growth Factor (VEGF) were increased in DME at baseline versus controls and decreased after SMPL treatments (p < 0.05). CRT reduction and visual acuity improvement were also found. Inflammatory cytokines, mainly produced by the retinal microglia, were significantly reduced after treatments, suggesting that SMPL may act by de-activating microglial cells, and reducing local inflammatory diabetes-related response.
Identifiants
pubmed: 31296907
doi: 10.1038/s41598-019-46515-y
pii: 10.1038/s41598-019-46515-y
pmc: PMC6624368
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
CCL5 protein, human
0
Chemokine CCL5
0
Cytokines
0
FASLG protein, human
0
Fas Ligand Protein
0
MAPKAP1 protein, human
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10034Références
Biomed Res Int. 2017;2017:1879437
pubmed: 28698867
Middle East Afr J Ophthalmol. 2012 Jan;19(1):70-4
pubmed: 22346117
Acta Ophthalmol. 2016 Feb;94(1):56-64
pubmed: 26268591
Curr Diabetes Rev. 2017;13(2):161-174
pubmed: 27748176
Proteomics Clin Appl. 2013 Aug;7(7-8):550-60
pubmed: 23418058
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):715-721
pubmed: 29392317
Ophthalmology. 2009 Jan;116(1):73-9
pubmed: 19118698
Clin Exp Ophthalmol. 2007 Sep-Oct;35(7):640-4
pubmed: 17894684
Mediators Inflamm. 2012;2012:493043
pubmed: 23055574
Glia. 2010 Apr 15;58(6):633-49
pubmed: 19941335
Retina. 2010 Jun;30(6):908-16
pubmed: 20168272
J Ophthalmol. 2018 Jan 17;2018:1694187
pubmed: 29576875
Prog Retin Eye Res. 2011 Sep;30(5):343-58
pubmed: 21635964
FASEB J. 2003 Jan;17(1):76-8
pubmed: 12475915
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Exp Eye Res. 2015 Jul;136:116-30
pubmed: 25952657
Invest Ophthalmol Vis Sci. 2013 Mar 01;54(3):2216-24
pubmed: 23439599
Graefes Arch Clin Exp Ophthalmol. 2005 Jan;243(1):3-8
pubmed: 15258777
Exp Eye Res. 2007 Jul;85(1):123-9
pubmed: 17493613
J Ophthalmol. 2014;2014:705783
pubmed: 25258680
Lancet Glob Health. 2013 Dec;1(6):e339-49
pubmed: 25104599
Surv Ophthalmol. 2018 May - Jun;63(3):307-328
pubmed: 28987614
Br J Ophthalmol. 2017 Nov;101(11):1518-1523
pubmed: 28270488
Acta Ophthalmol. 2017 Jun;95(4):e340-e341
pubmed: 27545866
Mol Vis. 2013;19:47-53
pubmed: 23335850
Dev Ophthalmol. 2017;60:16-27
pubmed: 28427061
Invest Ophthalmol Vis Sci. 2011 Jun 17;52(7):4314-23
pubmed: 21345996
Curr Med Chem. 2013;20(26):3267-71
pubmed: 23745552
Am J Ophthalmol. 2002 Jan;133(1):70-7
pubmed: 11755841
Diabetes Care. 2012 Mar;35(3):556-64
pubmed: 22301125
Ophthalmologica. 2017;238(1-2):81-88
pubmed: 28564655
Br J Ophthalmol. 2009 Oct;93(10):1341-4
pubmed: 19054831
Retina. 2017 Apr;37(4):761-769
pubmed: 27471825
Br J Ophthalmol. 2015 Aug;99(8):1065-9
pubmed: 25722492
Curr Diabetes Rev. 2012 Jul 1;8(4):274-84
pubmed: 22587512
JAMA Ophthalmol. 2018 Apr 1;136(4):382-388
pubmed: 29522144
Am J Physiol. 1987 Jan;252(1 Pt 2):F104-8
pubmed: 3812693
Ophthalmology. 2005 May;112(5):806-16
pubmed: 15878060
Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2760-6
pubmed: 15277502
Retina. 2020 Jan;40(1):126-134
pubmed: 30300267
Am J Ophthalmol. 2011 Oct;152(4):686-94
pubmed: 21782151
Prog Mol Biol Transl Sci. 2017;148:67-85
pubmed: 28662829
J Proteomics. 2011 Feb 1;74(2):151-66
pubmed: 20940065
Ophthalmologica. 2012;227(1):1-19
pubmed: 21921569
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Eye (Lond). 2008 Jan;22(1):42-8
pubmed: 16826241